Recruitment of T lymphocytes and induction of tumor necrosis factor in thyroid cancer by a local immunotherapy.
To elucidate the mechanism of action for intratumoral injection of immunopotentiators, infiltrating mononuclear cells and tumor necrosis factor (TNF) were assayed by immunostaining tissue samples of differentiated thyroid cancer resected with or without presurgical local application of OK-432, a streptococcal preparation. Frozen sections of resected specimens were stained with monoclonal antibodies using either a conventional or a modified immunoperoxidase method. The tumors injected with OK-432 showed increased T lymphocyte infiltration and HLA-DR expression on cancer cells as compared to the non-injected controls. Among these T cells, the CD4+ subset was more numerous than the CD8+ population. In four out of the seven cases constituting the injected group, numerous TNF-positive cells were seen in clusters or lines as well as scattered, while none of the seven cases in the control group was associated with a considerable amount of these cells. In their morphology and distribution pattern, these TNF-positive cells appeared to be of macrophage lineage. Thus local injection of OK-432 in thyroid cancer was shown to recruit T lymphocytes of predominantly the CD4+ subset and to induce in situ production of TNF, a known potent tumoricidal cytokine. The present data warrant further studies in this direction besides wider clinical intratumoral application of the reagent.
Misaki
T
T
Department of Nuclear Medicine, Kyoto University School of Medicine, Japan.
Watanabe
Y
Y
Iida
Y
Y
Hidaka
A
A
Kasagi
K
K
Fukushima
H
H
Konishi
J
J
D000328:Adult; D000368:Aged; D004801:Eosine Yellowish-(YS); D005260:Female; D006684:HLA-DR Antigens / Q000032:analysis; D006416:Hematoxylin; D006801:Humans; D007150:Immunohistochemistry; D007167:Immunotherapy; D016131:Lymphocyte Subsets / Q000187:drug effects / Q000276:immunology; D008264:Macrophages / Q000187:drug effects / Q000276:immunology; D008297:Male; D008875:Middle Aged; D010844:Picibanil / Q000627:therapeutic use*; D013601:T-Lymphocytes / Q000187:drug effects* / Q000276:immunology; D013964:Thyroid Neoplasms / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis*
D006684:HLA-DR Antigens; D014409:Tumor Necrosis Factor-alpha; D010844:Picibanil; D004801:Eosine Yellowish-(YS); D006416:Hematoxylin